Vasodilator therapy with ACE inhibitors and hydralazine is the mainstay of therapy in patient with chronic compensated mitral regurgitation. Acute mitral regurgitation requires urgent mitral valve repair or mitral valve replacement.  MV<unk>  is indicated in patients with chronic aortic regurgitation who develop symptomatic mitral valve regurgitation.  It is also indicated in patients with abnormalities in LV size or function (These include a left ventricular ejection fraction (LVEF) of less than 60% and a left ventricular end systolic dimension (LVESD) of greater than 45 mm), pulmonary hypertension, or new onset atrial fibrillation even without symptoms . The patient with severe LV dysfunction (an LVEF < 30% and/or a left ventricular end-systolic dimension greater than 55 mm) poses a higher risk but may undergo<unk>  if chordal preservation is likely.  MV repair is recommended over MV replacement in the majority of patients with severe chronic MR who require<unk> , and patients should be referred to surgical centers experienced in MV repair.
Mitral regurgitation surgery indications
Aortic regurgitation surgery indications
Mitral regurgitation surgery preoperative evaluation
Aortic regurgitation surgery valve selection
Mitral stenosis surgery preoperative evaluation
Cardiac resynchronization therapy indications
Mitral regurgitation surgery prognosis
Aortic stenosis surgery preoperative evaluation